Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevention of Neointimal Proliferation With Aggressive Reduction of Glucose Concentrations (Pioglitazone) Study -- PPAR-G -- An IVUS Pilot Feasibility Study in Type 2 Diabetic Patients.

NCT00819325 is registered in ClinicalTrials.gov with Queen Elizabeth II Health Sciences Centre as lead sponsor.

NCT NCT00819325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00819325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevention of Neointimal Proliferation With Aggressive Reduction of Glucose Concentrations (Pioglitazone) Study -- PPAR-G -- An IVUS Pilot Feasibility Study in Type 2 Diabetic Patients.
Lead sponsor
Queen Elizabeth II Health Sciences Centre
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2002
Completion date
March 31, 2007
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

angina pectoris, coronary artery disease, percutaneous coronary intervention, type 2 diabetes mellitus